Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AnaptysBio, Inc.
  6. Summary
    ANAB   US0327241065

ANAPTYSBIO, INC.

(ANAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
28.24(c) 27.44(c) 28.51(c) 28.53(c) 28.55 Last
181 613 314 945 75 874 101 893 94 819 Volume
-1.50% -2.83% +3.90% +0.07% +0.07% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 67,6 M - -
Net income 2021 -59,4 M - -
Net cash position 2021 327 M - -
P/E ratio 2021 -13,5x
Yield 2021 -
Sales 2022 52,3 M - -
Net income 2022 -98,7 M - -
Net cash position 2022 318 M - -
P/E ratio 2022 -8,38x
Yield 2022 -
Capitalization 783 M 783 M -
EV / Sales 2021 6,76x
EV / Sales 2022 8,88x
Nbr of Employees 94
Free-Float 99,4%
More Financials
Company
AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation... 
More about the company
Ratings of AnaptysBio, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ANAPTYSBIO, INC.
10/05ANAPTYSBIO : Releases Data From Phase 2 GALLOP Trial For Imsidolimab Drug, Wedbush Says; K..
MT
10/04ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu..
PU
10/04ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
10/04ANAPTYSBIO : Presents updated data from imsidolimab phase 2 gallop trial in generalized pu..
AQ
10/04ANAPTYSBIO : Mid-Stage Trial Shows Imsidolimab Drug Candidate May Have Potential Against P..
MT
10/02ANAPTYSBIO : Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pu..
AQ
10/02AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized P..
CI
09/10ANAPTYSBIO : Corporate Presentation September 2021
PU
09/09ANAPTYSBIO : to Participate in the H.C. Wainwright 23rd Annual Global Investment Conferenc..
AQ
08/18SECTOR UPDATE : Health Care Stocks Discounted Wednesday
MT
08/18SECTOR UPDATE : Health Care Stocks Underperforming Market Wednesday
MT
08/18ANAPTYSBIO : Fda grants accelerated approval of jemperli (dostarlimab-gxly) for dmmr recur..
AQ
08/18SECTOR UPDATE : Health Care Stocks Flat To Lower Premarket Wednesday
MT
08/18ANAPTYSBIO : Wedbush Lifts AnaptysBio's Price Target to $25 From $20 on Dostarlimab Update..
MT
08/18NORTH AMERICAN MORNING BRIEFING : Stock Futures Slip as Fed Minutes Eyed
DJ
More news
News in other languages on ANAPTYSBIO, INC.
10/04L'essai de mi-parcours d'AnaptysBio montre que le candidat-médicament Imsidolimab peut ..
2019AKTIEN NEW YORK SCHLUSS : Dow stagniert - Trump gibt den Partyschreck
2019AKTIEN NEW YORK : Dow im Minus - Trump gibt den Partyschreck
More news
Analyst Recommendations on ANAPTYSBIO, INC.
More recommendations
Chart ANAPTYSBIO, INC.
Duration : Period :
AnaptysBio, Inc. Technical Analysis Chart | ANAB | US0327241065 | MarketScreener
Technical analysis trends ANAPTYSBIO, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 28,55 $
Average target price 33,00 $
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Hamza Suria President, Chief Executive Officer & Director
Dennis M. Mulroy Chief Financial Officer
James N. Topper Chairman
Paul F. Lizzul Chief Medical Officer
Eric J. Loumeau Chief Operating Officer & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
ANAPTYSBIO, INC.32.79%783
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE241.44%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS18.47%59 196
VERTEX PHARMACEUTICALS-22.35%48 536